Results 51 to 60 of about 6,386 (141)

Développement d'un test colorimétrique pour tester la sensibilité de l'ADN polymérase du cytomégalovirus humain au foscarnet

open access: yes, 2005
We described a colorimetric method to determine the biochemical phenotype of wild-type and mutated cytomegalovirus (HCMV) DNA polymerases by measuring the incorporation of digoxigenin-labelled nucleotides into the growing DNA chain.
A.M. Fillet   +6 more
core   +1 more source

Nephrotoxicity induced by drugs: The case of foscarnet and atazanavirdA SEM and mFTIR investigation [PDF]

open access: yes, 2016
International audienceBiopsies of native or transplanted kidneys in patients suffering chronic or acute renal failure are commonly stained for tissue examination and search for possible crystal deposits which are then identified by polarizing microscopy ...
Frochot, Vincent   +11 more
core   +1 more source

Preparation and characterization of foscarnet/chitosan nanoparticles

open access: yes, 2010
Purpose: Foscarnet is an antiviral agent which inhibits the activity of herpesvirus DNA polymerase, including herpes simplex virus types 1 and 2, varicella zoster, cytomegalovirus, human immunodeficiency virus (HIV) and other viruses.
PARODI, BRUNELLA   +3 more
core  

Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG Protocol 093)

open access: yes, 1994
Objective: To document response to foscarnet salvage therapy in patients with cytomegalovirus (CMV) retinitis who are intolerant of or resistant to ganciclovir.
Murphy, Robert L.   +14 more
core   +1 more source

A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet

open access: yes, 2006
International audienceFoscarnet is currently licensed for the treatment of human cytomegalovirus (HCMV) infection. Mutations proven to confer resistance to foscarnet have mostly been mapped to regions II, III and VI of the HCMV UL54-encoded DNA ...
F. Petit   +11 more
core  

Design of Novel Derivatives of Phosphonoformate (Foscarnet) as Prodrugs and Antiviral Agents

open access: yes, 2016
Design of Novel Derivatives of Phosphonoformate (Foscarnet) as Prodrugs and Antiviral ...
Colin G. Ferguson (487955)   +2 more
core   +1 more source

Foscarnet therapy for congenital cytomegalovirus liver fibrosis following prenatal ascites

open access: yes, 2004
We report on an infant with multi-system disease including liver fibrosis, right microphthalmia with cataract, interstitial pneumonitis, and hyperechoic lesions in the basal ganglia and in the periventricular and thalamic regions.
L. Maranghi   +6 more
core   +1 more source

Traitement de 2éme ligne par Foscarnet des infections à Cytomégalovirus (CMV) chez les patients Allogreffes

open access: yes, 2015
INTRODUCTIONLes infections a cytomégalovirus sont des complications fréquentes aprés allogreffe de cellules souches hématopoeitiques. Le traitement de premiére intention reste le Ganciclovir, mais ce produit est asocié a des cytopénies ssévéres voir des ...
, A.Toma, S.Maury, C.Cordonier, C.Pautas   +1 more
core  

Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection

open access: yes
International audienceAbstract We evaluated Ibalizumab (IBA)-containing standardized optimized salvage regimen (with or without a 4-week foscarnet induction) in individuals harboring multidrug-resistant human immunodeficiency virus type 2 (HIV-2).
Caraux-Paz, Pauline   +191 more
core   +1 more source

Fast-atom bombardment mass spectrometric study of SATE Foscarnet prodrugs and of a series of Foscarnet-AZT conjugates

open access: yes, 1997
The mass spectrometric behaviour of a series of new derivatives of Foscarnet was studied with fast-atom bombardment and collision-induced dissociation experiments in positive- and negative-ion modes.
Herdewijn, Piet   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy